Nutra Pharma has announced the launch of Cobroxin, an over-the-counter (OTC) pain reliever formulated from cobra venom for the treatment of Stage 2 (moderate to severe) chronic pain. Cobroxin will be available in two OTC formulations, an oral spray and a topical gel.
Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has launched an over-the-counter (OTC) pain reliever, Cobroxin, for the treatment of Stage 2 (moderate to severe) chronic pain.
Cobroxin is the first OTC pain reliever clinically proven to treat Stage 2 (moderate to severe) chronic pain. The drug, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating repetitive stress, arthritis, and joint pain.
Additional benefits to Cobroxin include:
- All Natural
- More Potent than Morphine
- Long Lasting
“Cobroxin is a next generation pain reliever that addresses physician and consumer demand for a safer and less costly treatment for chronic pain,” commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “Cobroxin provides affordable and accessible pain relief for those without healthcare coverage, for those looking for a safer and effective treatment for pain, and for those not receiving effective or lasting relief from OTC NSAIDs,” he added.
Pain is the single most common reason patients seek medical care and accounts for half of all physician office visits in the United States. According to the American Pain Foundation, each year, more than 25 million people in the United States experience acute pain as a result of injury or surgery. Additionally, more than 50 million people in the United States are affected by ongoing chronic pain.
Current treatments for chronic pain include both opiate-based analgesics including Vicodin, Percocet, and Morphine, and those containing acetaminophen, such as Tylenol. Debate surrounding the use of opiates primarily focuses on the negative side effects observed with opiate-based analgesics, including nausea, vomiting, drowsiness, itching, constipation, respiratory depression, addiction, severe withdrawal symptoms and the buildup of tolerance, requiring higher dosage over time to experience the same effect. Additionally, recent media coverage has highlighted the dangers of using analgesics containing acetaminophen, which, in higher dosages, can cause liver damage or even death.
“What differentiates Cobroxin from other current analgesics is that it uses a novel mechanism of action discovered from cobra venom peptides for treating pain without the negative side effects observed in current opiate-based analgesics and those containing acetaminophen,” explained Dr. Paul Reid, CEO of Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm. “With extensive supporting evidence from 46 human clinical studies and a well-defined safety profile, we believe that Cobroxin will soon become the preferred method for treating chronic pain,” he concluded.
In preparation for commercializing Cobroxin, Nutra Pharma recently announced that ReceptoPharm had filed a patent application for a novel composition and method for oral delivery of cobra venom for the treatment of pain. The company plans to begin marketing and selling Cobroxin upon successful submission of final packaging and labeling to the FDA.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The launch of Cobroxin for the treatment of chronic pain should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.